WO2008090958A1 - Domain-exchanged recombinant antibody composition - Google Patents

Domain-exchanged recombinant antibody composition Download PDF

Info

Publication number
WO2008090958A1
WO2008090958A1 PCT/JP2008/050992 JP2008050992W WO2008090958A1 WO 2008090958 A1 WO2008090958 A1 WO 2008090958A1 JP 2008050992 W JP2008050992 W JP 2008050992W WO 2008090958 A1 WO2008090958 A1 WO 2008090958A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
domain
antibody composition
recombinant antibody
human igg1
Prior art date
Application number
PCT/JP2008/050992
Other languages
French (fr)
Japanese (ja)
Inventor
Kenya Shitara
Rinpei Niwa
Akito Natsume
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of WO2008090958A1 publication Critical patent/WO2008090958A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed are: a recombinant antibody composition which has the substitution of polypeptides respectively comprising CH1 domain and CH2 domain of the constant region in human IgG1 antibody by polypeptides respectively comprising amino acid sequences corresponding to the amino acid sequences located in the same positions in human IgG3 antibody as numbered according to the EU index as in Kabat et al. (hereinbelow, simply referred to as 'EU index'), and which has a higher CDC activity than those of human IgG1 antibody and human IgG3 antibody and a protein A-binding activity equivalent to that of human IgG1 antibody; an antibody molecule contained in the recombinant antibody composition or DNA encoding the heavy-chain constant region of the antibody molecule; a transformant produced by introducing the DNA into a host cell; a method for producing a recombinant antibody composition by using the transformant; and a pharmaceutical agent comprising the antibody composition as an active ingredient.
PCT/JP2008/050992 2007-01-24 2008-01-24 Domain-exchanged recombinant antibody composition WO2008090958A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-013642 2007-01-24
JP2007013642 2007-01-24

Publications (1)

Publication Number Publication Date
WO2008090958A1 true WO2008090958A1 (en) 2008-07-31

Family

ID=39644532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/050992 WO2008090958A1 (en) 2007-01-24 2008-01-24 Domain-exchanged recombinant antibody composition

Country Status (1)

Country Link
WO (1) WO2008090958A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051349A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Antibodies to ion channels
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
WO2011051351A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Method to generate antibodies to ion channels
WO2011118739A1 (en) 2010-03-26 2011-09-29 協和発酵キリン株式会社 Novel antibody having modification site introduced therein, and antibody fragment
WO2011123708A2 (en) 2010-03-31 2011-10-06 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
JP2012527234A (en) * 2009-05-20 2012-11-08 ファームアブサイン インコーポレイテッド Novel forms of dual target antibodies and uses thereof
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
US9346873B2 (en) 2008-09-30 2016-05-24 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US10618955B2 (en) 2014-07-15 2020-04-14 Kymab Limited Methods for treating neurodegenerative disease using anti-PD-1 antibodies
US10759867B2 (en) 2011-07-06 2020-09-01 Genmab B.V. Antibody variants and uses thereof
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
JP2021534801A (en) * 2018-08-29 2021-12-16 ユナイテッド バイオファーマ インコーポレイテッド Afcosilized antibody and its manufacturing method
US11753479B2 (en) 2014-03-04 2023-09-12 Kymab Limited Nucleic acids encoding anti-OX40L antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011041A1 (en) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. Genetically modified antibody composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011041A1 (en) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. Genetically modified antibody composition

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BREKKE O.H. ET AL.: "HUMAN IgG3 CAN ADOPT THE DISULFIDE BOND PATTERN CHARACTERISTIC FOR IgG1 WITHOUT RESEMBLING IT IN COMPLEMENT MEDIATED CELL LYSIS", MOL. IMMUNOL., vol. 30, no. 16, 1993, pages 1419 - 1425, XP023935453, DOI: doi:10.1016/0161-5890(93)90103-I *
DALL-ACQUA W.F. ET AL.: "Modulation of the Effector Functions of a human IgG1 through Engineering of Its Hinge Region", J. IMMUNOL., vol. 177, 2006, pages 1129 - 1138, XP002497452 *
KATO K. ET AL.: "13C NMR study of the mode of interaction in solution of the B fragment of staphyloccal protein A and the Fc fragments of mouse immunoglobulin G", FEBS LETT., vol. 328, no. 1-2, 1993, pages 49 - 54, XP025652646, DOI: doi:10.1016/0014-5793(93)80963-U *
SHIMIZU A. ET AL.: "1H NMR STUDIES OF THE Fc REGION OF HUMAN IgG1 AND IgG3 IMMUNOGLOBULINS: ASSIGNMENT OF HISTIDINE RESONANCES IN THE CH3 DOMAIN AND IDENTIFICATION OF IgG3 PROTEIN CARRYING G3m(st) ALLOTYPES", MOL. IMMUNOL., vol. 20, no. 2, 1983, pages 141 - 148, XP023786323, DOI: doi:10.1016/0161-5890(83)90124-4 *
THOMMESEN J.E. ET AL.: "Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation", MOL. IMMUNOL., vol. 37, 2000, pages 995 - 1004, XP002522213, DOI: doi:10.1016/S0161-5890(01)00010-4 *
VAN LOGHEM E. ET A.: "Staphyloccocal Protein A and Human IgG Subclasses and Allotypes", SCAND. J. IMMUNOL., vol. 15, no. 3, 1982, pages 275 - 278, XP008112596, DOI: doi:10.1111/j.1365-3083.1982.tb00649.x *
YAMANE-OHNUKI N. ET AL.: "Establishment of FUT8 Knockout Chinese Hamster Ovary Cells: An Ideal Host Cell Line for Producing Completely Defucosylated Antibodies With Enhanced Antibody-Dependent Cellular Cytotoxicity", BIOTECHNOL. BIOENG., vol. 87, no. 5, 2004, pages 614 - 622, XP002984450, DOI: doi:10.1002/bit.20151 *

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561123B2 (en) 2008-09-30 2020-02-18 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US20160219850A1 (en) * 2008-09-30 2016-08-04 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US20160222093A1 (en) * 2008-09-30 2016-08-04 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US9346873B2 (en) 2008-09-30 2016-05-24 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US10492476B2 (en) 2008-09-30 2019-12-03 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US10555506B2 (en) 2008-09-30 2020-02-11 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US10638736B2 (en) 2008-09-30 2020-05-05 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US10575504B2 (en) 2008-09-30 2020-03-03 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
JP2012527234A (en) * 2009-05-20 2012-11-08 ファームアブサイン インコーポレイテッド Novel forms of dual target antibodies and uses thereof
US10125194B2 (en) 2009-05-20 2018-11-13 Pharmabcine Inc. Dual targeting antibody of novel form, and use thereof
JP2015119705A (en) * 2009-05-20 2015-07-02 ファームアブサイン インコーポレイテッド Dual targeting antibody of novel form, and use thereof
US9067995B2 (en) 2009-10-27 2015-06-30 Ucb Pharma S.A. Method to generate antibodies to ion channels
US9738710B2 (en) 2009-10-27 2017-08-22 Ucb Biopharma Sprl Method of treating a patient for pain by administering an anti-ion channel antibody
WO2011051349A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Antibodies to ion channels
US8986954B2 (en) 2009-10-27 2015-03-24 Ucb Pharma S.A. DNA encoding function modifying Nav1.7 antibodies
US8926977B2 (en) 2009-10-27 2015-01-06 Ucb Pharma S.A. Antibodies to the E1 extracellular loop of ion channels
US10112996B2 (en) 2009-10-27 2018-10-30 Ucb Biopharma Sprl Function modifying NAv1.7 antibodies
US8734798B2 (en) 2009-10-27 2014-05-27 Ucb Pharma S.A. Function modifying NAv 1.7 antibodies
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
WO2011051351A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Method to generate antibodies to ion channels
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
US9956274B2 (en) 2009-10-27 2018-05-01 Ucb Biopharma Sprl Method to generate antibodies to ion channels
WO2011118739A1 (en) 2010-03-26 2011-09-29 協和発酵キリン株式会社 Novel antibody having modification site introduced therein, and antibody fragment
US10662255B2 (en) 2010-03-31 2020-05-26 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US10618977B2 (en) 2010-03-31 2020-04-14 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
KR101830020B1 (en) 2010-03-31 2018-02-19 아블렉시스, 엘엘씨 Genetic Engineering of non-human animals for the production of chimeric antibodies
KR20180018835A (en) * 2010-03-31 2018-02-21 아블렉시스, 엘엘씨 Genetic Engineering of non-human animals for the production of chimeric antibodies
KR20180030942A (en) * 2010-03-31 2018-03-26 아블렉시스, 엘엘씨 Genetic engineering of non-human animals for the production of chimeric antibodies
KR20180030941A (en) * 2010-03-31 2018-03-26 아블렉시스, 엘엘씨 Genetic engineering of non-human animals for the production of chimeric antibodies
KR101831117B1 (en) 2010-03-31 2018-04-04 아블렉시스, 엘엘씨 Genetic Engineering of non-human animals for the production of chimeric antibodies
KR101667440B1 (en) 2010-03-31 2016-10-18 아블렉시스, 엘엘씨 Genetic Engineering of non-human animals for the production of chimeric antibodies
US11352444B2 (en) 2010-03-31 2022-06-07 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US11242409B2 (en) 2010-03-31 2022-02-08 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
KR102004106B1 (en) 2010-03-31 2019-07-25 아블렉시스, 엘엘씨 Genetic Engineering of non-human animals for the production of chimeric antibodies
US10494445B2 (en) 2010-03-31 2019-12-03 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US11220555B2 (en) 2010-03-31 2022-01-11 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US10526420B2 (en) 2010-03-31 2020-01-07 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US11104744B2 (en) 2010-03-31 2021-08-31 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US11104743B2 (en) 2010-03-31 2021-08-31 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
EP2553100A4 (en) * 2010-03-31 2013-10-23 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US10604587B2 (en) 2010-03-31 2020-03-31 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
KR102203727B1 (en) 2010-03-31 2021-01-18 아블렉시스, 엘엘씨 Genetic engineering of non-human animals for the production of chimeric antibodies
US9580491B2 (en) 2010-03-31 2017-02-28 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US10626188B2 (en) 2010-03-31 2020-04-21 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
KR20130018259A (en) * 2010-03-31 2013-02-20 아블렉시스, 엘엘씨 Genetic engineering of non-human animals for the production of chimeric antibodies
WO2011123708A2 (en) 2010-03-31 2011-10-06 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
KR102117771B1 (en) 2010-03-31 2020-06-02 아블렉시스, 엘엘씨 Genetic engineering of non-human animals for the production of chimeric antibodies
US10836832B2 (en) 2010-03-31 2020-11-17 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US10829564B2 (en) 2010-03-31 2020-11-10 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
US10759867B2 (en) 2011-07-06 2020-09-01 Genmab B.V. Antibody variants and uses thereof
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
US11773175B2 (en) 2014-03-04 2023-10-03 Kymab Limited Antibodies, uses and methods
US11753479B2 (en) 2014-03-04 2023-09-12 Kymab Limited Nucleic acids encoding anti-OX40L antibodies
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US10618955B2 (en) 2014-07-15 2020-04-14 Kymab Limited Methods for treating neurodegenerative disease using anti-PD-1 antibodies
US10711059B2 (en) 2014-07-15 2020-07-14 Kymab Limited Methods for treating neurodegenerative diseases using anti-PD-L1 antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
JP2021534801A (en) * 2018-08-29 2021-12-16 ユナイテッド バイオファーマ インコーポレイテッド Afcosilized antibody and its manufacturing method
JP7216806B2 (en) 2018-08-29 2023-02-01 ユナイテッド バイオファーマ インコーポレイテッド Afucosylated antibody and method for producing same

Similar Documents

Publication Publication Date Title
WO2008090958A1 (en) Domain-exchanged recombinant antibody composition
EP1921090A4 (en) Genetically modified antibody composition
WO2008090960A1 (en) Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
WO2008090959A1 (en) Genetically recombinant antibody composition having enhanced effector activity
Newman et al. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019
CN102655877B (en) FGF21 mutants and application thereof
CN100404673C (en) Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
JP2021520192A (en) Trispecific binding molecule for cancer and its use
EP2705055B1 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
EP2441838A2 (en) Fusion proteins that contain natural junctions
EP2581113A4 (en) Anti-tim-3 antibody
WO2009133137A3 (en) Pegylated recombinant human growth hormone compounds
UA95636C2 (en) Improved sgp 130fc dimers
WO2003059951A3 (en) Novel anti-igf-ir antibodies and uses thereof
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
WO2006033700A3 (en) Her2 antibody composition
EP3178847B1 (en) Anti-tnf-alpha fully human monoclonal antibodies with low immunogenicity and application thereof
DE102004014983A1 (en) Recombinant polypeptides of the members of the TNF ligand family and their use
CN105073133A (en) Anti-gdf15 antibodies
BRPI0717363B8 (en) humanized immunoglobulin that specifically binds cd20, composition, recombinant vector, methods of obtaining a host cell, production of an immunoglobulin that specifically binds cd20, in viro to inhibit the growth or differentiation of a normal human b cell, and uses of immunoglobulin and a effective amount of immunoglobulin
SG187867A1 (en) Antibodies that bind myostatin, compositions and methods
NO20055209D0 (en) Peptabody for cancer treatment
TWI639440B (en) Liquid formulation comprising gm-csf neutralizing compound
SG194795A1 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08703819

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08703819

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP